Sulfadiazine

Sulfadiazine

SCHEMBL4098255

Nc1ccc(S(=O)(=O)Nc2ncccn2)cc1.[Ag].[Ag]

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

folP

The experimentally established mechanism targets of Sulfadiazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.96
AURKA O14965 1/20 0.96
DHFR P00374 1/20 0.96
TSHR P16473 1/20 0.96
SMN1; SMN2 Q16637 2/20 0.66
CYP2C9 P11712 2/20 0.65
MAPT P10636 2/20 0.65
ALDH1A1 P00352 4/20 0.59
TDP1 Q9NUW8 3/20 0.57
KMT2A Q03164 3/20 0.57
MEN1 O00255 1/20 0.57
CYP3A4 P08684 1/20 0.57
L3MBTL1 Q9Y468 3/20 0.56
PRMT1 Q99873 1/20 0.56
KDM4E B2RXH2 2/20 0.55
EDNRA P25101 1/20 0.55
SLC6A4 P31645 1/20 0.55
ADRA1A P35348 1/20 0.55
PRMT6 Q96LA8 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Sulfadiazine SCHEMBL3274530 1.00 LMNA (0.96) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL16860643 1.00 LMNA (0.96) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL34517 1.00 LMNA (0.96) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL27795518 0.98 LMNA (0.93) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL18668477 0.98 LMNA (0.93) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL10422849 0.98 LMNA (1.00) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL24176 0.98 LMNA (1.00) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL30080807 0.98 LMNA (1.00) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL5870705 0.96 LMNA (0.96) LMNAAURKADHFRTSHRSMN1; SMN2
Sulfadiazine SCHEMBL6141086 0.96 LMNA (0.96) LMNAAURKADHFRTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160151533-A1 COMPOSITIONS FOR TREATING BIOFILMS AND METHODS FOR USING SAME WILMINGTON TRUST, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2016-06-02 US claimed
US-20130101661-A1 COMPOSITIONS FOR TREATING BIOFILMS AND METHODS FOR USING SAME PLUROGEN THERAPEUTICS, INC. (US) 2013-04-25 US claimed
EP-2120561-A1 COMPOSITIONS FOR TREATING BIOFILMS AND METHODS FOR USING SAME Plurogen Therapeutics, Inc. (US) 2009-11-25 EP claimed
US-20090202615-A1 Compositions for Treating Biofilms and Methods for Using Same PLUROGEN THERAPEUTICS, INC. (US) 2009-08-13 US claimed
WO-2008103673-A1 COMPOSITIONS FOR TREATING BIOFILMS AND METHODS FOR USING SAME PLUROGEN THERAPEUTICS, INC. (US) 2008-08-28 WO claimed
CN-112890310-A Antibacterial underpants and preparation method thereof 泉州市锦恒服装实业有限公司 2021-06-04 CN disclosed
US-20190008993-A1 Compositions for Treating Biofilms and Methods for Using Same WILMINGTON TRUST, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2019-01-10 US disclosed
CN-108478843-A With the medical dressing and preparation method thereof containing copper coating 中国科学院金属研究所 2018-09-04 CN disclosed
US-9884136-B2 Compositions for treating biofilms and methods for using same PLUROGEN THERAPEUTICS, INC. (US) 2018-02-06 US disclosed
US-20170216480-A1 COMPOSITIONS FOR TREATING BIOFILMS AND METHODS FOR USING SAME WILMINGTON TRUST, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2017-08-03 US disclosed
EP-3170396-A1 COMPOSITIONS FOR TREATING BIOFILMS AND METHODS FOR USING SAME Plurogen Therapeutics, Inc. (US) 2017-05-24 EP disclosed
US-9603966-B2 Compositions for treating biofilms and methods for using same PLUROGEN THERAPEUTICS, INC. (US) 2017-03-28 US disclosed
US-20160151533-A1 COMPOSITIONS FOR TREATING BIOFILMS AND METHODS FOR USING SAME WILMINGTON TRUST, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2016-06-02 US disclosed
US-9283278-B2 Compositions for treating biofilms and methods for using same PLUROGEN THERAPEUTICS, INC. (US) 2016-03-15 US disclosed
US-20150099009-A1 COMPOSITIONS FOR TREATING BIOFILMS AND METHODS FOR USING SAME WILMINGTON TRUST, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT 2015-04-09 US disclosed
US-8871248-B2 Compositions for treating biofilms and methods for using same PLUROGEN THERAPEUTICS, INC. (US) 2014-10-28 US disclosed
US-20130101661-A1 COMPOSITIONS FOR TREATING BIOFILMS AND METHODS FOR USING SAME PLUROGEN THERAPEUTICS, INC. (US) 2013-04-25 US disclosed
EP-2120561-A1 COMPOSITIONS FOR TREATING BIOFILMS AND METHODS FOR USING SAME Plurogen Therapeutics, Inc. (US) 2009-11-25 EP disclosed
US-20090202615-A1 Compositions for Treating Biofilms and Methods for Using Same PLUROGEN THERAPEUTICS, INC. (US) 2009-08-13 US disclosed
WO-2008103673-A1 COMPOSITIONS FOR TREATING BIOFILMS AND METHODS FOR USING SAME PLUROGEN THERAPEUTICS, INC. (US) 2008-08-28 WO disclosed